Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie
PubMed
31054899
DOI
10.1016/j.humpath.2019.04.014
PII: S0046-8177(19)30079-6
Knihovny.cz E-zdroje
- Klíčová slova
- Diagnostic biomarker, Endometrial carcinoma, IMP3, L1CAM, Prognostic biomarker,
- MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- molekula buněčné adheze nervové L1 analýza biosyntéza MeSH
- nádorové biomarkery analýza MeSH
- nádory endometria patologie MeSH
- proteiny vázající RNA analýza biosyntéza MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- senzitivita a specificita MeSH
- stupeň nádoru metody MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Názvy látek
- IGF2BP3 protein, human MeSH Prohlížeč
- L1CAM protein, human MeSH Prohlížeč
- molekula buněčné adheze nervové L1 MeSH
- nádorové biomarkery MeSH
- proteiny vázající RNA MeSH
Discrimination between low- and high-grade endometrial carcinomas (ECs) is clinically relevant but can be challenging for pathologists, with moderate interobserver agreement. Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is an oncofoetal protein that is associated with nonendometrioid endometrial carcinomas but has been limited studied in endometrioid carcinomas. The aim of this study is to investigate the diagnostic and prognostic value of IMP3 in the discrimination between low- and high-grade ECs and its added value to L1CAM. IMP3 and L1CAM expression was assessed in tumors from 378 patients treated for EC at 1 of 9 participating European Network for Individualised Treatment of Endometrial Cancer centers. IMP3 was expressed in 24.6% of the tumors. In general, IMP3 was more homogeneously expressed than L1CAM. IMP3 expression was significantly associated with advanced stage, nonendometrioid histology, grade 3 tumors, deep myometrial invasion, lymphovascular space invasion, distant recurrences, overall mortality, and disease-related mortality. Simultaneous absence of IMP3 and L1CAM expression showed the highest accuracy for identifying low-grade carcinomas (area under the curve 0.766), whereas simultaneous expression of IMP3 and L1CAM was strongly associated with high-grade carcinomas (odds ratio 19.7; 95% confidence interval 9.2-42.2). Even within endometrioid carcinomas, this combination remained superior to IMP3 and L1CAM alone (odds ratio 8.6; 95% confidence interval 3.4-21.9). In conclusion, IMP3 has good diagnostic value and together with L1CAM represents the optimal combination of diagnostic markers for discrimination between low- and high-grade ECs compared to IMP3 and L1CAM alone. Because of the homogenous expression of IMP3, this marker might be valuable in preoperative biopsies when compared to the more patchy L1CAM expression.
Department of Obstetrics and Gynaecology Hospital del Mar 8003 Barcelona Spain
Department of Pathology Canisius Wilhelmina Hospital 6500 GS Nijmegen the Netherlands
Department of Pathology Ghent University Hospital 9000 Ghent Belgium
Department of Pathology Hospital del Mar 8003 Barcelona Spain
Department of Pathology Radboud University Medical Centre 6500HB Nijmegen the Netherlands
Department of Pathology University of Turku 20500 Turku Finland
Obstetrics and Gynaecology Department Bichat Claude Bernard Hospital 75877 Paris France
Pathology Department Bichat Claude Bernard Hospital 75877 Paris France
Pathology Department Vall Hebron University Hospital 8035 Barcelona Spain
Citace poskytuje Crossref.org